nSTRIDE APS in Females With Primary Patellofemoral Osteoarthritis

Inclusion Criteria: * Patient must be female * Isolated patellofemoral osteoarthritis (PFOA) in one or both knees as diagnosed by the treating physician * Objective evidence of PFOA on one or both of a radiograph or MRI taken within 3 months of treatment * From 40-65 years of age, inclusive at time of injection * Symptoms return such that there is a need for further treatment within 3 months of a corticosteroid or hyaluronic acid injection * Willing and able to comply with the study procedures * Sign informed consent form Exclusion Criteria: * Any systematic inflammatory condition (e.g. rheumatoid arthritis) * Active malignancy at time of injection * Pregnant at time of injection * Lactating at time of injection * Knee joint infections or skin diseases or infections in the area of the injection site * Leukemia, metastatic malignant cells, or who are receiving chemotherapeutic treatment * Participation in another device, biologic or drug study